Equities research analysts expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) to report ($0.19) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings, with estimates ranging from ($0.23) to ($0.15). Oramed Pharmaceuticals posted earnings of ($0.17) per share in the same quarter last year, which would suggest a negative year over year growth rate of 11.8%. The firm is expected to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Oramed Pharmaceuticals will report full year earnings of ($0.80) per share for the current fiscal year, with EPS estimates ranging from ($0.98) to ($0.51). For the next financial year, analysts anticipate that the firm will report earnings of ($0.95) per share, with EPS estimates ranging from ($1.41) to ($0.48). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Oramed Pharmaceuticals.
ORMP has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of Oramed Pharmaceuticals in a research note on Thursday, March 17th. Cantor Fitzgerald initiated coverage on shares of Oramed Pharmaceuticals in a report on Friday, February 18th. They issued an “overweight” rating and a $20.00 price target for the company. Finally, StockNews.com initiated coverage on shares of Oramed Pharmaceuticals in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $31.40.
In related news, Director Kevin Rakin sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 21st. The shares were sold at an average price of $9.41, for a total value of $94,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.90% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Voya Investment Management LLC lifted its position in Oramed Pharmaceuticals by 5.1% in the 3rd quarter. Voya Investment Management LLC now owns 11,291 shares of the biotechnology company’s stock worth $248,000 after buying an additional 549 shares in the last quarter. Close Asset Management Ltd grew its stake in Oramed Pharmaceuticals by 26.8% in the third quarter. Close Asset Management Ltd now owns 3,170 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 670 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Oramed Pharmaceuticals by 2.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 65,707 shares of the biotechnology company’s stock valued at $939,000 after purchasing an additional 1,456 shares in the last quarter. Morgan Jess S & Co. Inc. grew its stake in Oramed Pharmaceuticals by 0.7% in the fourth quarter. Morgan Jess S & Co. Inc. now owns 215,401 shares of the biotechnology company’s stock valued at $3,076,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Oramed Pharmaceuticals by 9.2% in the 3rd quarter. Deutsche Bank AG now owns 18,727 shares of the biotechnology company’s stock worth $411,000 after purchasing an additional 1,578 shares during the last quarter. 17.28% of the stock is currently owned by hedge funds and other institutional investors.
About Oramed Pharmaceuticals (Get Rating)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
- Get a free copy of the StockNews.com research report on Oramed Pharmaceuticals (ORMP)
- The Sherwin-Williams Company Bottoms Above Institutional Support
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
- Whirlpool Is A Steal At These Prices
- Kimberly-Clark Pops On Successful Price Pass-Through
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.